Daunorubicin
- Generic Name
- Daunorubicin
- Brand Names
- Cerubidine, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO10
- CAS Number
- 20830-81-3
- Unique Ingredient Identifier
- ZS7284E0ZP
- Background
A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.
- Indication
For remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults.
...
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Chronic Phase Chronic Myeloid Leukemia, Ewing's Sarcoma, Lymphoma, Diffuse, Myeloblastic Leukemia, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Wilms' tumor
- Associated Therapies
- -
Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03419494
- Locations
- 🇨🇳
Affiliated Hospital of Guangdong Medical University, Guangdong, Guangdong, China
Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)
- Conditions
- Interventions
- First Posted Date
- 2018-01-04
- Last Posted Date
- 2020-02-05
- Target Recruit Count
- 4000
- Registration Number
- NCT03390387
- Locations
- 🇷🇺
Morozov Children's Municipal Clinical Hospital, Moscow, Russian Federation
🇦🇲prof. R.O.Eolyan Hematology Center, Ereván, Armenia
🇷🇺Transbaikal Regional Oncology Dispensary, Chita, Russian Federation
Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
- Conditions
- Interventions
- First Posted Date
- 2017-10-02
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03298984
- Locations
- 🇺🇸
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Columbia University, New York, New York, United States
ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
- First Posted Date
- 2017-09-18
- Last Posted Date
- 2022-09-28
- Target Recruit Count
- 60
- Registration Number
- NCT03286634
- Locations
- 🇯🇵
Kagoshima University Hospital, Kagoshima, Japan
🇲🇾University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- Drug: AzacitidineDrug: DecitabineDrug: CytarabineDrug: DaunorubicinDrug: EtoposideCombination Product: ITMHADrug: IdarubicinDrug: FludarabineDrug: MitoxantroneDrug: SorafenibDrug: Erwinia asparaginaseDrug: G-CSFDrug: DexrazoxaneDrug: Asparaginase Erwinia Chrysanthemi, Recombinant-RywnBiological: Stem Cell Transplant
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 206
- Registration Number
- NCT03164057
- Locations
- 🇺🇸
Rady Children's Hospital and Health Center, San Diego, California, United States
🇺🇸Children's Hospital of Central California, Madera, California, United States
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
- Conditions
- Interventions
- First Posted Date
- 2017-05-01
- Last Posted Date
- 2020-03-06
- Lead Sponsor
- Gilead Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT03135028
- Locations
- 🇯🇵
University of Fukui Hospital, Fukui, Japan
🇯🇵Tokai University Hospital, Kanagawa, Japan
🇯🇵Tohoku University Hospital, Miyagi, Japan
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
- Conditions
- Interventions
- Drug: PrednisoneDrug: VincristineDrug: DaunorubicinDrug: PegaspargaseDrug: Erwinase®Drug: CyclophosphamideDrug: CytarabineDrug: MercaptopurineDrug: DasatinibDrug: MethotrexateDrug: BlinatumomabDrug: DexamethasoneDrug: RuxolitinibDrug: ThioguanineDrug: BortezomibDrug: Asparaginase Erwinia chrysanthemi (recombinant)-rywnDrug: Calaspargase PegolDrug: DoxorubicinDrug: EtoposideDrug: NelarabineDrug: ClofarabineDrug: VorinostatDrug: Idarubicin
- First Posted Date
- 2017-04-18
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 790
- Registration Number
- NCT03117751
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT02954653
- Locations
- 🇺🇸
Wake Forest Baptist Health, Winston-Salem, North Carolina, United States
🇺🇸The University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸Banner-University Medical Center Tucson, Tucson, Arizona, United States
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-09-26
- Last Posted Date
- 2022-01-14
- Lead Sponsor
- Tara Lin
- Target Recruit Count
- 18
- Registration Number
- NCT02914977
- Locations
- 🇺🇸
University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States
Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 500
- Registration Number
- NCT02894645
- Locations
- 🇲🇾
University of Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾Subang Jaya Medical Centre, Subang Jaya, Malaysia
🇸🇬National University Hospital, Singapore, Singapore
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.